What Is a Stress Test With Myocardial Perfusion?

A stress test with myocardial perfusion is a two-part cardiac imaging exam that maps blood flow through your heart muscle under both stress and rest conditions, revealing whether any regions are starved for oxygen. A small amount of radioactive tracer is injected into your bloodstream and taken up by heart cells in proportion to how much blood they receive, then a specialized camera captures images of that tracer distribution. Areas that light up normally at rest but go dark during stress point to arteries with significant blockages. The test has become one of the most common non-invasive tools for diagnosing coronary artery disease and, just as importantly, for predicting whether you’re at risk for a heart attack in the years ahead.

How the Test Works at a Basic Level

The logic behind myocardial perfusion imaging is straightforward. When your heart is pushed to work harder, healthy coronary arteries widen to deliver more blood. Arteries narrowed by plaque cannot widen as much, so the heart muscle they supply falls behind. By comparing images taken during peak stress with images taken at rest, doctors can see exactly where that mismatch occurs. A region that looks normal at rest but shows reduced tracer uptake under stress is considered “ischemic,” meaning it’s not getting enough blood when demand spikes. A region that looks abnormal in both sets of images usually represents scar tissue from a prior heart attack.

This simultaneous look at perfusion and function gives the test a “one stop” quality that few other cardiac exams match. Modern gated imaging (where the camera syncs with your heartbeat) can also assess how well your heart squeezes, adding wall-motion information on top of the blood-flow map.¹

Exercise Stress Versus Pharmacologic Stress

If you can walk briskly on a treadmill, the standard approach is an exercise stress test. You’ll start at a slow pace and a gentle incline, and the speed and grade increase every few minutes following a standardized protocol. The goal is to push your heart rate up to at least 85 percent of your age-predicted maximum, at which point the tracer is injected while you keep walking for another minute or so. Exercise stress is generally preferred because it also provides useful information about your fitness level, blood pressure response, and any symptoms or ECG changes that show up with exertion.

Many patients, though, cannot exercise hard enough. Severe arthritis, peripheral vascular disease, deconditioning, or pulmonary problems can all make treadmill testing unreliable. In those cases, a pharmacologic agent substitutes for exercise. For years, the main options were adenosine and dipyridamole, both of which work by dilating coronary arteries. Healthy arteries dilate much more than diseased ones, creating the same kind of blood-flow mismatch you’d see with exercise. Since 2008, regadenoson has largely replaced the older agents in the United States because it is simpler to administer (a single fixed-dose injection rather than a continuous infusion) and causes fewer side effects.² In a large phase 3 trial, regadenoson proved equally effective at detecting reversible ischemia compared with adenosine.

Even with pharmacologic stress, side effects are common but usually brief. Flushing, headache, chest tightness, and a feeling of shortness of breath are reported frequently and typically resolve within minutes. Some people feel a brief wave of nausea or lightheadedness. Aminophylline, a caffeine-like drug, can be given intravenously to reverse the effects quickly if needed.

What Happens to the Tracer Inside Your Heart

The radiotracers used in perfusion imaging are designed to be taken up by living heart muscle cells in proportion to blood flow. The two most widely used tracers are technetium-99m–labeled compounds called sestamibi and tetrofosmin. Both are attracted to the electrical charge across the membranes of mitochondria, the tiny energy factories inside each cell. Once inside, the tracer essentially gets trapped there, giving the camera enough time to take detailed pictures. Research on isolated heart cells has shown that tetrofosmin uptake happens within seconds of being exposed to active mitochondria and is driven almost entirely by the negative electrical potential across the mitochondrial membrane.³

This mechanism matters clinically because it means the tracer reflects not just blood delivery but the metabolic health of the heart cells themselves. Dead or severely damaged tissue won’t accumulate the tracer well regardless of blood supply, which is why fixed defects (dark spots in both stress and rest images) indicate scar rather than reversible ischemia. The practical upshot: the images tell your cardiologist whether a problem is potentially fixable with a stent or bypass surgery, or whether the damage has already been done.

SPECT and PET Cameras

Most myocardial perfusion imaging in the United States and worldwide is performed with SPECT (single photon emission computed tomography) cameras. A SPECT camera rotates around your chest, collecting gamma rays emitted by the technetium-based tracer, and reconstructs a 3D map of tracer distribution throughout your heart muscle. Gated SPECT, which captures images in sync with your ECG, can assess both perfusion and heart-wall motion in a single study.¹

PET (positron emission tomography) is a newer and less widely available alternative. PET cameras have higher spatial resolution and can also measure absolute myocardial blood flow in quantitative terms, which SPECT generally cannot. In a substudy of a large phase 3 clinical trial, PET significantly outperformed SPECT in detecting coronary disease in patients with smaller hearts. The diagnostic accuracy of SPECT dropped from an area under the curve of 0.75 in larger hearts down to 0.67 in smaller hearts, while PET held steady at 0.77 to 0.79 regardless of heart size. That gap was driven largely by women, who tend to have smaller left ventricles.⁴ Despite these advantages, PET remains less accessible due to higher cost and the need for an on-site cyclotron or generator for some tracers, so SPECT continues to be the workhorse for most cardiology practices.

PET’s ability to quantify blood flow in absolute numbers (milliliters per gram per minute) opens another diagnostic window. A metric called coronary flow reserve, which compares peak-stress blood flow to resting blood flow, can detect diffuse disease across all three coronary arteries that might look deceptively normal on a relative perfusion map.⁵ When every artery is equally narrowed, relative images can appear “balanced” because no region stands out as worse than the others, and the disease gets missed. Absolute flow measurement catches that pattern.

Why Caffeine Matters So Much Before Your Test

If you’re scheduled for pharmacologic stress with adenosine, dipyridamole, or regadenoson, you’ll be told to avoid caffeine for at least 12 to 24 hours beforehand. This isn’t just a suggestion. Caffeine blocks the same adenosine receptors these drugs are designed to activate, directly undermining the test’s ability to produce a meaningful difference in blood flow between healthy and diseased arteries.

A prospective, randomized multicenter study tested what happens when patients consume caffeine before a regadenoson stress perfusion scan. Both 200 mg and 400 mg doses of caffeine (roughly one to two cups of coffee) significantly reduced the number of heart segments where reversible defects could be detected. Among patients who had three or more ischemic segments on a caffeine-free scan, the vast majority showed fewer ischemic segments after caffeine exposure.⁶ In practical terms, drinking coffee before a pharmacologic stress test can make real blockages invisible on the images.

A separate study using adenosine stress with cardiac MRI confirmed the same problem: caffeine significantly reduced the measured perfusion reserve in normal heart segments, narrowing the gap between healthy and ischemic tissue and making it harder to tell them apart.⁷ If you accidentally drink coffee or an energy drink before a pharmacologic stress test, tell the lab immediately. The test may need to be rescheduled. For exercise stress tests, caffeine restriction is less critical because the stress mechanism does not depend on adenosine receptors, though many labs still recommend avoiding it.

Artifacts and False Results

No imaging test is perfect, and perfusion scans are susceptible to several types of artifacts that can mimic or mask disease. Soft-tissue attenuation is the most common culprit. In women, breast tissue can absorb some of the gamma rays before they reach the camera, creating the appearance of reduced tracer uptake in the heart wall underneath. A study using newer cadmium-zinc-telluride (CZT) cameras found that women frequently showed visible inferior wall defects in the upright position due to pendant breast tissue. In roughly a third of these women, the defect was more pronounced during the stress phase than at rest, falsely suggesting ischemia.⁸

In men, the diaphragm can create a similar attenuation pattern along the bottom of the heart. Imaging in both the supine and prone positions, or using software-based attenuation correction, helps labs distinguish real defects from shadows. Patient motion during scanning is another problem. Even small shifts between the stress and rest acquisitions can create artificial mismatches. Modern cameras with shorter scan times have reduced but not eliminated motion artifacts.

How Well the Test Predicts Future Events

One of the strongest arguments for myocardial perfusion imaging is its prognostic power. The test doesn’t just tell your doctor whether you have coronary disease right now. It grades the severity in a way that predicts your risk of heart attack or cardiac death over the following years. A study of obese patients followed for an average of five and a half years found that the annual cardiac death rate was 0.6 percent in those with normal perfusion compared with 3.3 percent in those with abnormal perfusion. The annual hard cardiac event rate (including nonfatal heart attacks) was 1 percent versus 4.8 percent.⁹ Patients with abnormalities spread across multiple coronary territories had an even higher death rate than those with single-vessel patterns.

Perfusion imaging adds prognostic information on top of what doctors already know from your symptoms, risk factors, and exercise capacity. In a large study comparing men and women, nuclear imaging improved risk stratification in both sexes after accounting for clinical and exercise variables. The added value was statistically significant regardless of whether the patient started with a high or low estimated likelihood of coronary disease.¹⁰

The test also has value after bypass surgery or stenting. A systematic review covering nearly 13,000 patients who had previously undergone revascularization found that an abnormal perfusion or stress echocardiography result was associated with roughly double the risk of hard cardiac events and about five times the risk of cardiac death compared with a normal result.¹¹ Nuclear imaging can help guide decisions about whether repeat procedures are warranted in patients whose symptoms return after treatment.¹²

Testing in Larger Patients

Body size has historically been a concern for SPECT imaging because extra tissue between the heart and the camera degrades image quality. Reassuringly, a study using gated SPECT with combined supine and prone positioning (without software attenuation correction) found that diagnostic accuracy for detecting coronary artery disease was similar across normal-weight, overweight, and obese patients.¹³ A separate study confirmed that diagnostic-quality images were achievable in 98 percent of morbidly obese patients when labs used dual-head cameras, attenuation correction, and higher tracer doses. Exercise stress, when feasible, was associated with better image quality in this group.¹⁴

There is one caveat. The prognostic “warranty” of a normal scan may be shorter in morbidly obese patients than in thinner ones. A normal result in the general population is often taken to indicate low risk for at least two years, but the reassurance window appears narrower when body mass index is very high, likely because of the accelerated progression of atherosclerosis associated with severe obesity.

Radiation Exposure and Low-Dose Protocols

The radioactive tracer delivers a small dose of radiation, which is a legitimate concern when millions of perfusion scans are performed annually. Traditional SPECT protocols using both stress and rest injections of a technetium-based tracer deliver a total effective dose in the range of 8 to 12 millisieverts, comparable to a few years of natural background radiation. But newer cameras and protocols have brought this down dramatically. A study using a high-efficiency CZT camera with a stress-first imaging protocol found that the average effective dose for a complete study was just 2.2 millisieverts. Among the roughly 70 percent of patients whose stress images were normal (meaning they did not need the rest injection at all), the average dose was under 1 millisievert.¹⁵ That’s in the same ballpark as a mammogram.

The stress-first approach is key to these reductions. If the stress images look completely normal, there’s no clinical need for the rest images, and the patient is spared the second injection and its associated radiation. This strategy works particularly well in chest-pain populations where a large proportion of patients turn out to have normal hearts.

How Perfusion Imaging Compares With CT Angiography

Coronary CT angiography (CCTA) has emerged as a strong competitor to nuclear perfusion imaging for evaluating chest pain. Rather than measuring blood flow, CCTA directly visualizes the coronary arteries and identifies plaque. A study comparing the two head-to-head against invasive catheterization found that CCTA had substantially higher sensitivity for detecting significant blockages. For lesions narrowing an artery by more than 50 percent, CT sensitivity was about 99 percent compared to 56 percent for SPECT perfusion imaging. The tradeoff was in specificity: CT’s specificity was 74 percent versus 39 percent for perfusion imaging.¹⁶

Those numbers might make CT look like the obvious winner, but the story is more nuanced. CCTA excels at ruling disease out (its negative predictive value is very high), while perfusion imaging excels at answering a different question: does this blockage actually limit blood flow enough to matter? A 50 percent narrowing visible on CT might not cause any ischemia at all, and treating it with a stent wouldn’t help. Perfusion imaging captures the functional consequence of anatomic disease, which is often what drives treatment decisions. Many centers now use both tests in a complementary fashion, starting with CT to rule out disease in lower-risk patients and reserving perfusion imaging for those with known or suspected blockages where the functional significance is unclear.

The Role of Artificial Intelligence

AI is beginning to reshape how perfusion images are processed and read. Machine learning algorithms can calculate perfusion scores more consistently than manual visual assessment, reducing the variability that inevitably comes with human readers. The concept of using AI to improve standard metrics like total perfusion deficit (a number that quantifies how much of the heart muscle shows reduced blood flow) has shown promising results, with the major practical advantage that these tools can slot into existing image-processing software rather than requiring entirely new systems.¹⁷

Deep learning is also being applied to image reconstruction itself. Older SPECT cameras required lengthy acquisition times to collect enough data for clean images, but neural networks trained on large datasets can produce high-quality reconstructions from lower-count data, which means shorter scans and lower tracer doses. The technology is still maturing, and most labs use AI as a second reader alongside a human cardiologist rather than as a standalone interpreter. But for a test that has been around since the 1980s, the integration of AI represents the most significant technical evolution in a generation.

Beta-Blockers and Other Medications

Patients often worry about whether their heart medications will interfere with the test. Beta-blockers, which slow heart rate and lower blood pressure, are a particular concern because they can blunt the heart-rate response during exercise and potentially reduce the sensitivity of the study. For pharmacologic stress, the picture is different. A study of 555 patients who underwent vasodilator perfusion imaging and subsequent coronary angiography found that both the sensitivity and specificity of the test were similar whether or not patients were taking beta-blockers.¹⁸ Because vasodilator agents work by relaxing blood vessels rather than by raising heart rate, beta-blockers don’t undermine their mechanism the way they can undermine an exercise test.

In practice, whether you should stop beta-blockers before your test depends on which type of stress you’re getting and your doctor’s preference. For exercise stress, many cardiologists ask patients to hold beta-blockers for 24 to 48 hours if it is safe to do so. For pharmacologic stress, the evidence suggests continuing them is fine. Other medications with specific guidance include calcium channel blockers (sometimes held before exercise stress) and theophylline-containing drugs (held before adenosine-based stress because they block the same receptors caffeine does).